首页> 外文期刊>Cancer biology & therapy >Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery
【24h】

Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery

机译:食管鳞状细胞癌的定量组织蛋白质组学研究新的生物标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Esophageal squamous cell carcinoma (ESCC) is among the top ten most frequent malignancies worldwide. In this study, our objective was to identify potential biomarkers for ESCC through a quantitative proteomic approach using the isobaric tags for relative and absolute quantitation (iTRaQ) approach. We compared the protein expression profiles of ESCC tumor tissues with the corresponding adjacent normal tissue from ten patients. LC-MS/MS analysis of strong cation exchange chromatography fractions was performed on an accurate Mass QTOF mass spectrometer, which led to the identification of 687 proteins. In all, 257 proteins were identified as differentially expressed in ESCC as compared with normal. We found several previously known protein biomarkers to be upregulated in ESCC including thrombospondin 1 (THBS1), periostin 1 (POSTN) and heat shock 70 kDa protein 9 (HSPA9) confirming the validity of our approach. In addition, several novel proteins that had not been reported previously were identified in our screen. These novel biomarker candidates included prosaposin (PSAP), plectin 1 (PLEC1) and protein disulfide isomerase a 4 (PDIA4) that were further validated to be overexpressed by immunohistochemical labeling using tissue microarrays. The success of our study shows that this mass spectrometric strategy can be applied to cancers in general to develop a panel of candidate biomarkers, which can then be validated by other techniques.
机译:食道鳞状细胞癌(ESCC)是全球十大最常见的恶性肿瘤之一。在这项研究中,我们的目标是通过定量蛋白质组学方法,使用等压标记的相对和绝对定量(iTRaQ)方法,识别ESCC的潜在生物标记。我们比较了来自十名患者的ESCC肿瘤组织和相应的邻近正常组织的蛋白质表达谱。在精确的质谱QTOF质谱仪上对强阳离子交换色谱馏分进行LC-MS / MS分析,从而鉴定出687种蛋白质。与正常相比,在ESCC中总共鉴定出257种差异表达的蛋白质。我们发现ESCC中一些先前已知的蛋白质生物标志物被上调,包括血小板反应蛋白1(THBS1),骨膜素1(POSTN)和热休克70 kDa蛋白9(HSPA9),证实了我们方法的有效性。此外,在我们的筛选中还发现了一些以前没有报道过的新型蛋白质。这些新的生物标志物候选物包括prosaposin(PSAP),plectin 1(PLEC1)和蛋白质二硫键异构酶a 4(PDIA4),这些蛋白已通过使用组织微阵列的免疫组织化学标记进一步证实过表达。我们研究的成功表明,这种质谱策略可普遍应用于癌症,以开发一组候选生物标志物,然后可通过其他技术对其进行验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号